Human Coagulation Factor VIII

also known as Optivate

Milestone	Jurisdiction	Brand	Indication	Date	Sentence it was read from
Approved	EU (EMA)	Voncento	—	2013-08-12	europa.eu ↗

today

EU approved 2013

NCT02246868 · Ph 3

200120022003200420052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027

Phase	Registry id	Dates	Indication	Sponsor	Status	Outcome
Phase 31 trial
Phase 3	NCT02246868	Sep 2001 → Aug 2004	hemophilia A	Bio Products Laboratory	Completed	No outcome recorded
Comparator or background therapy1 trial
Phase 3	NCT07416526 Comparator	May 2026 → Sep 2027 expected	hemophilia A	Hoffmann-La Roche	Recruiting	No outcome recorded

Every value below carries the sentence it was read from. 2 sources stand behind the page.

Field	Value	Cited text
Known as	Human Coagulation Factor VIII	ClinicalTrials.gov intervention name — accepted as the source's own label NCT02246868 ↗ 1 NCT07416526 ↗
Known as	Optivate	“Optivate® (Human Coagulation Factor VIII)” NCT02246868 ↗
Action	Restore	“whether haemostasis was achieved with Optivate® when treating a bleed” NCT02246868 ↗
Modality	Protein / enzyme biologic	“Optivate® (Human Coagulation Factor VIII)” NCT02246868 ↗